scholarly journals Applicability of a Modified Rat Model of Acute Arthritis for Long-Term Testing of Drug Delivery Systems

Pharmaceutics ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 70 ◽  
Author(s):  
Imke Rudnik-Jansen ◽  
Nina Woike ◽  
Suzanne de Jong ◽  
Sabine Versteeg ◽  
Marja Kik ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Total Duration ◽  
Delivery Systems ◽  
Pain Behavior ◽  
Streptococcal Cell Wall ◽  
Arthritis Model ◽  
Acute Arthritis ◽  
Analgesic Effects

Episodes of inflammation and pain are predominant features of arthritic joint diseases. Drug delivery systems (DDS) could reduce inflammation and pain long-term without chances of infection upon multiple injections. To allow for long-term evaluation of DDS, we modified a previously published acute arthritis model by extending follow-up periods between flare-ups. Unilateral synovial inflammation of the knee was induced by intra-articular injection of streptococcal cell wall peptidoglycan polysaccharide (PGPS), and flare-ups were induced by intravenous PGPS injections every 4 weeks for a total duration of 84 days. In PGPS-reactivated animals, joint swelling, pain behavior, post mortem synovitis, and osteophyte formation were notable features. Hepatitis, splenitis and inflammation of non-primed joints were observed as systemic side effects. To test the applicability of the modified arthritis model for long-term testing of DDS, the duration of anti-inflammatory and analgesic effects of a corticosteroid released from two different polymer-based platforms was evaluated. The current modified arthritis model has good applicability for testing of DDS for a prolonged period of time. Furthermore, the novel autoregulatory polyesteramide (PEA) microsphere platform releasing triamcinolone acetonide (TAA) was benchmarked against poly lactic-co-glycolic acid (PLGA) and reduced joint swelling and pain behavior more potently compared to TAA-loaded PLGA microspheres.

BioMEMS Technologies for Regenerative Medicine

2008 ◽  
Vol 1139 ◽  
Author(s):  
Jeffrey T. Borenstein
Keyword(s):  
Drug Delivery ◽  
Regenerative Medicine ◽  
Drug Delivery Systems ◽  
Ex Vivo ◽  
Delivery Systems ◽  
Organ Shortage ◽  
Engineered Tissues ◽  
Drug Concentrations

AbstractThe emergence of BioMEMS fabrication technologies such as soft lithography, micromolding and assembly of 3D structures, and biodegradable microfluidics, are already making significant contributions to the field of regenerative medicine. Over the past decade, BioMEMS have evolved from early silicon laboratory devices to polymer-based structures and even biodegradable constructs suitable for a range of ex vivo and in vivo applications. These systems are still in the early stages of development, but the long-term potential of the technology promises to enable breakthroughs in health care challenges ranging from the systemic toxicity of drugs to the organ shortage. Ex vivo systems for organ assist applications are emerging for the liver, kidney and lung, and the precision and scalability of BioMEMS fabrication techniques offer the promise of dramatic improvements in device performance and patient outcomes.Ultimately, the greatest benefit from BioMEMS technologies will be realized in applications for implantable devices and systems. Principal advantages include the extreme levels of achievable miniaturization, integration of multiple functions such as delivery, sensing and closed loop control, and the ability of precision microscale and nanoscale features to reproduce the cellular microenvironment to sustain long-term functionality of engineered tissues. Drug delivery systems based on BioMEMS technologies are enabling local, programmable control over drug concentrations and pharmacokinetics for a broad spectrum of conditions and target organs. BioMEMS fabrication methods are also being applied to the development of engineered tissues for applications such as wound healing, microvascular networks and bioartificial organs. Here we review recent progress in BioMEMS-based drug delivery systems, engineered tissue constructs and organ assist devices for a range of ex vivo and in vivo applications in regenerative medicine.

Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome

Pain Medicine ◽  
2018 ◽  
Vol 20 (3) ◽  
pp. 515-520 ◽  
Author(s):  
Eric Z Herring ◽  
Leonardo A Frizon ◽  
Olivia Hogue ◽  
Jay U Mejia ◽  
Richard Rosenquist ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Complex Regional Pain Syndrome ◽  
Drug Delivery Systems ◽  
Pain Syndrome ◽  
Delivery Systems ◽  
Long Term Outcomes ◽  
Intrathecal Drug Delivery

scholarly journals Sustained-release drug delivery systems for the treatment of glaucoma

2021 ◽  
Vol 14 (1) ◽  
pp. 148-159
Author(s):  
Natasha P. Kesav ◽  
◽  
Monica K. Ertel ◽  
Leonard K. Seibold ◽  
Malik Y. Kahook ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Sustained Release ◽  
Targeted Delivery ◽  
Drug Delivery Systems ◽  
Patient Adherence ◽  
The United States ◽  
Delivery Systems ◽  
Release Drug ◽  
Systemic Side Effects

Glaucoma, a leading cause of irreversible blindness, affects more than 64 million people worldwide and is expected to grow in number due to the aging global population and enhanced methods of detection. Although topical therapies are often effective when used as prescribed, the drawbacks of current medical management methods include poor patient adherence, local and systemic side effects, and in some cases, limited therapeutic efficacy. Novel ocular drug delivery platforms promise to deliver differentiated drug formulations with targeted delivery leveraging patient-independent administration. Several platforms are in various stages of development with promising pre-clinical and clinical data. The Bimatoprost Sustained Release (SR) intracameral implant was approved in the United States in March of 2020, making it the first long-term injectable therapy available for the treatment of glaucoma. This review aims to provide an update on novel sustained release drug delivery systems that are available today as well as those that might be commercialized in coming years.

scholarly journals Electrospun organic–inorganic nanohybrids as sustained release drug delivery systems

2017 ◽  
Vol 5 (46) ◽  
pp. 9165-9174 ◽  
Author(s):  
Yanshan Gao ◽  
Tian Wei Teoh ◽  
Qiang Wang ◽  
Gareth R. Williams
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Sustained Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Release Drug

Novel organic–inorganic nanohybrids have been prepared, and are found to provide long-term extended drug release.

Use of Lipids, Polymers, and Peptides for Drug Delivery and Targeting to Cancer Cells or Specific Organs

2021 ◽  
pp. 276-289
Author(s):  
Sampan Attri ◽  
Shruti Sharma ◽  
Ujjawal Sharma ◽  
Manjita Srivastava ◽  
Subash C. Sonkar ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Delivery Systems ◽  
Structural Characteristics ◽  
Delivery Systems ◽  
Chemotherapeutic Agents ◽  
Delivery Methods ◽  
Practical Applications ◽  
Low Cytotoxicity

Cancer has been the most deleterious disease in recent times, and unfortunately its spread is increasing. Systemic treatment with chemotherapeutics remains the conventional way of treating many cancers, despite the serious damage long-term chemotherapy can cause in healthy tissues. Many therapeutic strategies have achieved popular practical applications, but drug delivery systems still face challenges associated with safety, and this has led to the development of safer drug delivery methods composed of biocompatible substances. In this respect, lipid-, polymer-, and peptide-based drug delivery systems have been proposed as safer candidates for cancer therapy. These delivery methods are expected to as biodegradable systems with low cytotoxicity for cancer therapy. Therefore, in this chapter, the authors discuss use of lipids, polymers, and peptides as delivery vehicles for chemotherapeutic agents and their structural characteristics.

scholarly journals Osteoinductive 3D scaffolds prepared by blend centrifugal spinning for long-term delivery of osteogenic supplements

RSC Advances ◽  
2018 ◽  
Vol 8 (39) ◽  
pp. 21889-21904 ◽  
Author(s):  
Lukasova Vera ◽  
Buzgo Matej ◽  
Vocetkova Karolina ◽  
Kubíková Tereza ◽  
Tonar Zbyněk ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Bone Regeneration ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
3D Scaffolds ◽  
Centrifugal Spinning ◽  
Term Delivery

Bone regeneration is a long-term process requiring proper scaffolding and drug delivery systems.

777 COMPLICATIONS OF LONG-TERM INTRASPINAL DRUG DELIVERY SYSTEMS

2006 ◽  
Vol 10 (S1) ◽  
pp. S202b-S202
Author(s):  
I. Vrba ◽  
I. Štìtkáøová ◽  
J. Kozák
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems
Sign in / Sign up

Export Citation Format

Share Document